bioAffinity reports Q2 2026 CyPath Lung test volume up 216% year over year

bioAffinity Technologies reported second quarter 2026 results on August 7, 2026, saying CyPath Lung diagnostic test volume increased 216% during the second quarter of 2026 compared to the second quarter of 2025.¹ The company said the longitudinal clinical trial designed to evaluate the clinical performance of the CyPath Lung test has begun patient enrollment at 11 clinical sites, including nine Department of Veterans Affairs and military medical centers, with financial support from the John P. Murtha Cancer Center Research Program, a research program within the Department of Surgery at the Uniformed Services University of the Health Sciences in Bethesda, Maryland.¹

The company also disclosed pipeline updates outside CyPath Lung. It said positive preliminary therapeutic data support the development of topical treatments for squamous and basal cell skin cancers, with self-delivering stabilized siRNAs selectively killing melanoma, squamous and basal carcinoma cells while sparing healthy cutaneous cells.¹ Separately, bioAffinity said it announced a collaboration with Pictor, Inc., a targeted proteomic platform company, to support development and commercialization of bioAffinity Technologies' next-generation diagnostic tests designed to provide a more complete picture of lung inflammation in patients with asthma and COPD.¹

On financing, the company noted it completed a public offering in June 2026 that generated approximately $3.2 million in gross proceeds to support commercialization activities, clinical development, and general corporate purposes.¹

For the quarter, cash and cash equivalents as of June 30, 2026, were $2.4 million, compared with $6.4 million as of December 31, 2025.¹ The company reported a net loss of $3.4 million for the quarter ended June 30, 2026, compared with a net loss of $4.1 million for the second quarter of 2025.¹